PLG-101 is an innovative first-in-class monoclonal antibody developed by POLYGON Therapeutics, aimed at transforming the treatment landscape for cardiovascular diseases. By specifically targeting the immune response during myocardial infarction, PLG-101 seeks to improve cardiac remodeling post-ischemia, offering hope for enhanced patient outcomes in a field where new therapeutic approaches are critically needed. This project benefits from a collaborative effort involving top French research institutions and has already demonstrated promising results in preclinical models.

Basic information

Country

FRANCE

Group Name

POLYGON Therapeutics

Source

Source